N/A
Completed N=163
Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)
Arthritis, Psoriatic
Source: ClinicalTrials.gov NCT00725296 ↗
Enrolled (actual)
163
Serious AEs
3.7%
Results posted
Jul 2011
Primary outcomePrimary: Mean Time Interval Between Infusions During Maintenance Therapy — 57.03; 57.90; 58.59; 56.02 days
Summary
This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Time Interval Between Infusions During Maintenance Therapy |
57.03; 57.90; 58.59; 56.02; 56.92; 59.32 | — |
| PRIMARY Median Time Interval Between Infusions During Maintenance Therapy |
56; 56; 56; 56; 56; 56 | — |
| PRIMARY Average Dose During Induction Therapy and Subsequent Maintenance Therapy |
3.92; 3.92; 3.98; 3.96; 3.94; 3.94 | — |
| PRIMARY Median Dose During Induction Therapy and Subsequent Maintenance Therapy |
3.75; 3.75; 3.75; 3.75; 3.75; 3.75 | — |
| PRIMARY Average Overall Dose of All Infusions Per Participant |
4.07 | — |
| PRIMARY Median Dose of All Infusions Per Participant |
3.87 | — |
Eligibility Criteria
Inclusion Criteria
- Participants with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drugs.
Exclusion Criteria
- All according to contraindications in the label especially:
- Participants with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections.
- Participants with moderate or severe heart failure (NYHA class III/IV).
- Participants with a history of hypersensitivity to infliximab or to other murine proteins, or to any of the excipients.
Data sourced from ClinicalTrials.gov (NCT00725296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.